Neurobiology of aging Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• A neural implementation of cognitive reserve: Insights from a longitudinal fMRI study of set-switching in aging..  76-83. 2024
• Hypothalamic MRI-derived microstructure is associated with neurocognitive aging in humans..  102-112. 2024
• The relationship between cortical thickness and white matter hyperintensities in mid to late life..  129-139. 2024
• Cognitive reserve proxies are associated with age-related cognitive decline - Not age-related gait speed decline..  46-54. 2024
• Reserve, resilience and maintenance of episodic memory and other cognitive functions in aging..  60-69. 2024
• Elevated protease-activated receptor 4 (PAR4) gene expression in Alzheimer's disease predicts cognitive decline..  93-101. 2024
• Childhood engagement in cognitively stimulating activities moderates relationships between brain structure and cognitive function in adulthood..  36-44. 2024
• Personality traits and cognitive reserve-High openness benefits cognition in the presence of age-related brain changes..  38-46. 2024
• Perivascular space burden interacts with APOE-ε4 status on cognition in older adults..  1-8. 2024
• Changes in an in-vivo classifier of ARTerioloSclerosis (ARTS) with simultaneous change in cognition for older African Americans..  21-27. 2023
• In vivo tau is associated with change in memory and processing speed, but not reasoning, in cognitively unimpaired older adults..  28-38. 2023
• Effect of short-term androgen supplementation on cognitive performance in older male rhesus macaques..  246-249. 2023
• Moderating role of physical activity on hippocampal iron deposition and memory outcomes in typically aging older adults..  124-131. 2023
• Extracellular matrix proteoglycans support aged hippocampus networks: a potential cellular-level mechanism of brain reserve..  52-58. 2023
• Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease..  103-113. 2023
• Sleep quality and sleep duration predict brain microstructure among community-dwelling older adults..  90-97. 2023
• Multi-omic characterization of brain changes in the vascular endothelial growth factor family during aging and Alzheimer's disease..  25-33. 2023
• Whole blood transcript and protein abundance of the vascular endothelial growth factor family relate to cognitive performance..  11-17. 2023
• A framework for concepts of reserve and resilience in aging..  100-103. 2022
• Enlarged perivascular space burden associations with arterial stiffness and cognition..  85-97. 2022
• Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults..  52-63. 2022
• Biological correlates of elevated soluble TREM2 in cerebrospinal fluid..  88-98. 2022
• RNASE6 is a novel modifier of APOE-ε4 effects on cognition..  66-76. 2022
• Predicting future cognitive decline from non-brain and multimodal brain imaging data in healthy and pathological aging..  55-65. 2022
• Cerebrovascular response to exercise interacts with individual genotype and amyloid-beta deposition to influence response inhibition with aging..  15-26. 2022
• Cognitively stimulating environments and cognitive reserve: the case of personal social networks..  197-203. 2022
• Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults..  181-190. 2022
• Associations of deformation-based brain morphometry with cognitive level and decline within older Blacks without dementia..  35-43. 2021
• Association between WWOX/MAF variants and dementia-related neuropathologic endophenotypes..  95-106. 2021
• Brain-predicted age difference is associated with cognitive processing in later-life..  195-203. 2021
• Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease..  90-98. 2021
• Red cell distribution width, anemia and their associations with white matter integrity among middle-aged urban adults..  229-240. 2021
• Age-dependent relationship of cardiorespiratory fitness and white matter integrity..  48-56. 2021
• Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults..  109-116. 2021
• Sleep, rest-activity rhythms and aging: a complex web in Alzheimer's disease?.  102-103. 2021
• Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25..  64-72. 2021
• KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers..  123-129. 2021
• Education and age-related differences in cortical thickness and volume across the lifespan..  102-110. 2020
• Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability..  116-123. 2020
• Metabolic syndrome and its components in relation to in vivo brain amyloid and neurodegeneration in late middle age..  89-96. 2020
• Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain..  165-175. 2020
• Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease..  233-245. 2020
• MicroRNA predicts cognitive performance in healthy older adults..  186-194. 2020
• Relationship between neural functional connectivity and memory performance in age-related macular degeneration..  176-185. 2020
• Free-water metrics in medial temporal lobe white matter tract projections relate to longitudinal cognitive decline..  15-23. 2020
• Optimized prediction of cognition based on brain morphometry across the adult life span..  16-24. 2020
• Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults..  124-130. 2020
• Estimating brain age based on a uniform healthy population with deep learning and structural magnetic resonance imaging..  15-25. 2020
• Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls..  84-92. 2020
• Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease..  102-111. 2019
• Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-α in APOE4 carriers..  112-122. 2019
• Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience..  124-129. 2019
• What are the later life contributions to reserve, resilience, and compensation?.  140-144. 2019
• Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment..  11-21. 2019
• The relationship between white matter hyperintensities and cognitive reference abilities across the life span..  31-41. 2019
• Associations between modifiable risk factors and white matter of the aging brain: insights from diffusion tensor imaging studies..  56-70. 2019
• Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid..  178-185. 2019
• Cognitive aging is not created equally: differentiating unique cognitive phenotypes in "normal" adults..  13-19. 2019
• Seizures as an early symptom of autosomal dominant Alzheimer's disease..  18-23. 2018
• Genetic analysis of neurodegenerative diseases in a pathology cohort..  214.e1-214.e9. 2018
• In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies..  171-181. 2018
• Sex-dependent effect of the BDNF Val66Met polymorphism on executive functioning and processing speed in older adults: evidence from the health ABC study..  161-170. 2018
• Modeling white matter tract integrity in aging with diffusional kurtosis imaging..  265-275. 2018
• Neurofilament relates to white matter microstructure in older adults..  233-241. 2018
• Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies..  111-116. 2018
• Telomere attrition is associated with declines in medial temporal lobe volume and white matter microstructure in functionally independent older adults..  68-75. 2018
• APOE genotype modifies the association between central arterial stiffening and cognition in older adults..  120-127. 2018
• Language processing in age-related macular degeneration associated with unique functional connectivity signatures in the right hemisphere..  65-74. 2017
• Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults..  64-71. 2017
• Association of anti-inflammatory cytokine IL10 polymorphisms with motoric cognitive risk syndrome in an Ashkenazi Jewish population..  238.e1-238.e8. 2017
• Long-term changes in time spent walking and subsequent cognitive and structural brain changes in older adults..  153-161. 2017
• Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease..  25-32. 2017
• Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples..  83-92. 2017
• Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2..  193.e17-193.e25. 2017
• Alzheimer's-related cortical atrophy is associated with postoperative delirium severity in persons without dementia..  55-63. 2017
• Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults..  141-147. 2016
• Cognitive reserve moderates the association between functional network anti-correlations and memory in MCI..  152-162. 2016
• Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age..  149-156. 2016
• Widespread white matter and conduction defects in PSEN1-related spastic paraparesis..  201-209. 2016
• Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease..  68-75. 2016
• Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models..  159-172. 2016
• Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease..  177-88. 2016
• Differences between chronological and brain age are related to education and self-reported physical activity..  138-144. 2016
• The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume..  68-77. 2016
• Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring..  61-67. 2015
• Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome..  151-163. 2015
• Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly..  36:3247-3254. 2015
• Breadth and age-dependency of relations between cortical thickness and cognition..  36:3020-3028. 2015
• Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14 years in older adults..  36:3038-3044. 2015
• NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure..  36:2533-43. 2015
• Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes..  36:2501-8. 2015
• Serum IGF-BP2 strongly moderates age's effect on cognition: a MIMIC analysis..  36:2232-2240. 2015
• Brain atrophy and white-matter hyperintensities are not significantly associated with incidence and severity of postoperative delirium in older persons without dementia..  36:2122-9. 2015
• Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers..  36:1771-9. 2015
• Declines in inflammation predict greater white matter microstructure in older adults..  36:948-54. 2014
• Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study..  36:1097-104. 2014
• Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease..  35:2883.e3-2883.e10. 2014
• Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence..  36:27-32. 2014
• Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits..  36:265-72. 2014
• Trajectories of inflammatory markers and cognitive decline over 10 years..  35:2785-2790. 2014
• Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis..  S29-34. 2014
• Dietary and lifestyle guidelines for the prevention of Alzheimer's disease..  S74-8. 2014
• Physical activity, body mass index, and brain atrophy in Alzheimer's disease..  36 Suppl 1:S194-S202. 2014
• Amyloid burden and neural function in people at risk for Alzheimer's Disease..  35:576-84. 2013
• Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models..  34:1581-8. 2013
• Functional connectivity and graph theory in preclinical Alzheimer's disease..  35:757-68. 2013
• Missense variant in TREML2 protects against Alzheimer's disease..  35:1510.e19-26. 2013
• FUS is not dysregulated by the spinal bulbar muscular atrophy androgen receptor polyglutamine repeat expansion..  34:1516.e17-9. 2012
• Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals..  34:822-31. 2012
• Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease..  34:1-12. 2012
• Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative..  34:62-72. 2012
• Toward a multifactorial model of Alzheimer disease..  33:2262-71. 2012
• Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume..  33:1124.e31-41. 2011
• Potential of functional MRI as a biomarker in early Alzheimer's disease..  32 Suppl 1:S37-43. 2011
• Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment..  33:2113-24. 2011
• A genome-wide association study of aging..  32:2109.e15-28. 2011
• Age and amyloid-related alterations in default network habituation to stimulus repetition..  33:1237-52. 2011
• CSF biomarkers for Alzheimer's disease: current utility and potential future use..  32 Suppl 1:S4-9. 2011
• White matter lesions and brain gray matter volume in cognitively normal elders..  33:834.e7-16. 2011
• Effects of ApoE4 and maternal history of dementia on hippocampal atrophy..  33:856-66. 2010
• 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects..  31:1284-303. 2010
• Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series..  33:426.e13-21. 2010
• Obesity is linked with lower brain volume in 700 AD and MCI patients..  31:1326-39. 2010
• Telomere length and cognitive function in community-dwelling elders: findings from the Health ABC Study..  32:2055-60. 2009
• White matter hyperintensities and cognition: testing the reserve hypothesis..  32:1588-98. 2009
• Age-related changes in glutamate release in the CA3 and dentate gyrus of the rat hippocampus..  32:811-20. 2009
• Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal..  31:1077-88. 2008
• Cardiovascular risk and memory in non-demented elderly women..  31:1250-3. 2008
• Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function..  31:1089-98. 2008
• Serum leptin level and cognition in the elderly: Findings from the Health ABC Study..  30:1483-9. 2008
• Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease..  31:1188-96. 2008
• The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease..  30:672-81. 2007
• Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J..  30:257-65. 2007
• A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice..  29:836-47. 2007
• Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death..  28:1709-17. 2006
• Age-related changes in brain activation during a delayed item recognition task..  28:784-98. 2006
• Structural MRI covariance patterns associated with normal aging and neuropsychological functioning..  28:284-95. 2006
• Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response..  28:238-47. 2006
• Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?.  27:524-9. 2005
• Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment..  27:394-401. 2005
• Hippocampal and neocortical activation during repetitive encoding in older persons..  27:173-82. 2005
• Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases..  26:1183-92. 2004
• Divergence of the apoptotic pathways induced by 4-hydroxynonenal and amyloid beta-protein..  25:1057-66. 2004
• Obesity enhances verbal memory in postmenopausal women with Down syndrome..  25:159-66. 2004
• Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies..  24:969-76. 2003
• Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice..  24:245-58. 2003
• Use of YFP to study amyloid-beta associated neurite alterations in live brain slices..  24:1071-7. 2003
• Abeta conformational change is central to Alzheimer's disease..  23:1085-8. 2002
• Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al..  23:671-4; discussion 683-4. 2002
• Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E..  22:683-9. 2001
• Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition..  22:721-7. 2001
• NGF expression in the aged rat pineal gland does not correlate with loss of sympathetic axonal branches and varicosities..  20:685-93. 1999
• Neurotrophin receptor and tyrosine hydroxylase gene expression in aged sympathetic neurons..  18:67-79. 1997
• Synthetic amyloid beta-protein fails to produce specific neurotoxicity in monkey cerebral cortex..  13:561-7. 1992

Identity

International Standard Serial Number (ISSN)

• 0197-4580
• 1558-1497